Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2014
Same author

Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor.

Thrombosis research·2014
Same author

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.

Blood·2012
Same author

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

Blood·2011
Same author

Tissue factor and factor VIIa cross-species compatibility.

Frontiers in bioscience (Landmark edition)·2011
Same author

Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2011

Related Experiment Video

Updated: Jul 2, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Microarray studies of factor VIIa-activated cancer cells.

Lars Christian Petersen1

  • 1Haemostasis Biology, Novo Nordisk, Maalov, Denmark. LCP@novonordisk.com

Thrombosis Research
|August 12, 2008
PubMed
Summary

Tissue Factor (TF) and Factor VIIa (FVIIa) activate Protease Activated Receptor 2 (PAR2), influencing cellular activities. Gene profiling reveals distinct gene expression patterns induced by TF:FVIIa via PAR2 compared to thrombin via PAR1.

More Related Videos

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

Related Experiment Videos

Last Updated: Jul 2, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Factor VIIa (FVIIa) signaling relies on Tissue Factor (TF) and Protease Activated Receptors (PARs).
  • FVIIa primarily signals through PAR2, differing from thrombin's PAR1 signaling mechanism.
  • TF:FVIIa-mediated activities are linked to inflammation, atherosclerosis, angiogenesis, and tumor progression.

Purpose of the Study:

  • To investigate cellular responses to coagulation factors, specifically FVIIa.
  • To compare gene expression profiles induced by FVIIa via PAR2 and thrombin via PAR1.
  • To elucidate the distinct gene repertoires activated by these signaling pathways.

Main Methods:

  • Gene-expression profiling of MDA-MB-231 cells stimulated with FVIIa or PAR1/PAR2 agonist peptides.
  • Quantitative PCR (qPCR) to measure transcription of selected genes.
  • Analysis of carcinoma cell lines.

Main Results:

  • Identified novel gene expression patterns induced by PAR activation.
  • Characterized the specific gene repertoire induced by TF:FVIIa via PAR2.
  • Highlighted differences in gene expression compared to thrombin-induced PAR1 activation.

Conclusions:

  • FVIIa signaling through PAR2 induces a unique set of genes.
  • Understanding these distinct pathways offers insights into coagulation factor-mediated cellular functions.
  • This research contributes to knowledge of cancer biology and related processes.